Original Research
Baseline CD4 and mortality trends in the South African human immunodeficiency virus programme: Analysis of routine data
Submitted: 05 March 2019 | Published: 24 July 2019
About the author(s)
Rivka R. Lilian, Anova Health Institute, Johannesburg, South AfricaKate Rees, Anova Health Institute, Johannesburg, South Africa; and, School of Public Health and Family Medicine, University of Cape Town, Cape Town, South Africa
Moyahabo Mabitsi, Anova Health Institute, Johannesburg, South Africa
James A. McIntyre, Anova Health Institute, Johannesburg, South Africa; and, School of Public Health and Family Medicine, University of Cape Town, Cape Town, South Africa
Helen E. Struthers, Anova Health Institute, Johannesburg, South Africa; and, Division of Infectious Diseases and HIV Medicine, Department of Medicine, University of Cape Town, Cape Town, South Africa
Remco P.H. Peters, Anova Health Institute, Johannesburg, South Africa; and, School of Public Health, University of the Witwatersrand, Johannesburg, South Africa; and, Department of Medical Microbiology, School of Public Health and Primary Care (CAPHRI), Maastricht University Medical Centre, Maastricht, the, Netherlands
Abstract
Background: Despite widespread availability of antiretroviral therapy (ART) in South Africa, there remains a considerable burden of human immunodeficiency virus (HIV)-related morbidity and mortality.
Objectives: To describe ART initiation and outcome trends over time, with a focus on clients presenting with advanced HIV-infection, so as to identify interventions to reduce morbidity and mortality.
Methods: Routine TIER.Net data from HIV-infected adults who had a documented baseline CD4 count and were newly initiating ART in Johannesburg or Mopani districts from 2004 to 2017 were analysed. Trends in baseline CD4 count and 5-year mortality were investigated and the population initiating ART with CD4 < 200 cells/mm3 was described.
Results: The Johannesburg and Mopani data sets comprised 203 131 and 101 814 records, respectively. Although median CD4 count increased over time, the proportion of initiations at CD4 < 200 cells/mm3 in 2017 remained high (Johannesburg 39%, Mopani 35%). Mortality was significantly increased among clients with CD4 < 200 compared to those with higher baseline counts (p < 0.001). Even though mortality among clients with low CD4 declined over time, likely because of improved drug regimens, in 2016–2017 mortality was still significantly increased among these clients (p < 0.001). Delivery of cotrimoxazole prophylaxis to clients with low CD4 declined over time to < 30% in 2017 and was associated with clinical stage. Presentation with CD4 < 200 cells/mm3 was associated with older age, male gender and hospitalisation.
Conclusion: A concerningly large proportion of South Africans still initiate ART at low CD4 counts. This is associated with increased mortality and requires targeted interventions to improve delivery of prophylactic regimens and early engagement in care.
Keywords
Metrics
Total abstract views: 3312Total article views: 3945
Crossref Citations
1. Prevalence of HIV, viral hepatitis B/C and tuberculosis and treatment outcomes among people who use drugs: Results from the implementation of the first drop-in-center in Mozambique
Cynthia Semá Baltazar, Timothy A. Kellogg, Makini Boothe, Anne Loarec, Ernesto de Abreu, Manuel Condula, Erika Fazito, Henry F. Raymond, Marleen Temmerman, Stanley Luchters
International Journal of Drug Policy vol: 90 first page: 103095 year: 2021
doi: 10.1016/j.drugpo.2020.103095